Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 7Active not recruiting 3Terminated 2Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 78Melanoma 51Squamous Cell Carcinoma of Head and Neck 40Neoplasm Metastasis 30Neoplasms 27Breast Neoplasms 26Colorectal Neoplasms 23Carcinoma, Renal Cell 23Head and Neck Neoplasms 21Triple Negative Breast Neoplasms 20Carcinoma, Transitional Cell 20Stomach Neoplasms 19Ovarian Neoplasms 17Lung Neoplasms 15Uterine Cervical Neoplasms 12Esophageal Neoplasms 12Carcinoma, Hepatocellular 12Urinary Bladder Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Pancreatic Neoplasms 10Small Cell Lung Carcinoma 9Multiple Myeloma 9Recurrence 8Endometrial Neoplasms 8Carcinoma, Merkel Cell 8Lymphoma, Non-Hodgkin 7Lymphoma 7Skin Neoplasms 6Mesothelioma 6Hodgkin Disease 6

Interventions

tislelizumab 3Paclitaxel 3Nivolumab 3pembrolizumab 2atezolizumab 2Docetaxel 2ulocuplumab 1tazemetostat 1tazarotene 1seviteronel 1rucaparib 1romiplostim 1phosphorylethanolamine 1pertuzumab 1neratinib 1magrolimab 1fluzoparib 1fludarabine 1epacadostat 1durvalumab 1camrelizumab 1Trastuzumab 1Sunitinib 1Poly(ADP-ribose) Polymerase Inhibitors 1LY2510924 1EC145 1Cyclophosphamide 1CH5183284 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Solid Tumor × pembrolizumab × Clear all
NCT03588039 2023-05-19

Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

Athenex, Inc.

Phase 1 Terminated
34 enrolled
Other solid neoplasm

Solid Tumor

NCT03894540 2022-09-13

Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

Ipsen

Phase 1 Terminated
22 enrolled 27 charts
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡